4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances
D Molecular Therapeutics, Inc. ( (FDMT) ) has released its Q3 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc.
Scotiabank Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), ...
After Gemini, Imagen 3's text-to-image capabilities land on Google Docs
Google Docs users rejoice, Google's Imagen 3, the tech giant's most advanced AI text-to-image generator, is now rolling out ...
Nasdaq9h
Glossary of Stock Market Terms
Whether you're a new investor or a seasoned pro, it helps to have a solid glossary at your fingertips to provide quick clarification on a particular term or to expand your overall stock market ...
MarketWatch23h
Micron Technology Inc.
Samsung Electronics Co. Ltd. 7.21% ₩357.15T ...